Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PHGE 
Biomx Inc (PHGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PHGE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.23% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.69M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 2 | Beta 1.46 | 52 Weeks Range 0.34 - 1.16 | Updated Date 10/17/2025 |
52 Weeks Range 0.34 - 1.16 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.14% | Return on Equity (TTM) -79.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27783541 | Price to Sales(TTM) - |
Enterprise Value 27783541 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.25 | Shares Outstanding 26554887 | Shares Floating 18019163 |
Shares Outstanding 26554887 | Shares Floating 18019163 | ||
Percent Insiders 18.81 | Percent Institutions 44.48 |
Upturn AI SWOT
Biomx Inc
Company Overview
History and Background
BiomX Inc. is a clinical-stage biotechnology company focused on developing phage therapy products to treat chronic diseases. Founded in Israel, the company leverages its expertise in microbiome analysis and phage biology to discover and develop targeted therapies.
Core Business Areas
- Phage Therapy Development: Focuses on identifying and developing phage-based therapies for a range of diseases, including inflammatory bowel disease (IBD) and cancer.
- Microbiome Research: Conducts research to understand the role of the microbiome in various diseases and identifies potential therapeutic targets.
Leadership and Structure
The company has a management team experienced in biotechnology and pharmaceutical development. The organizational structure includes research, development, and clinical operations departments.
Top Products and Market Share
Key Offerings
- BX001 (Acne treatment): A topical phage therapy product for the treatment of acne vulgaris, targeting Cutibacterium acnes. Competitors include traditional antibiotics and topical retinoids. Market share data not available.
- BX211 (IBD treatment): An oral phage therapy product targeting Klebsiella pneumoniae for the treatment of inflammatory bowel disease (IBD). Competitors include biologics and small molecule drugs. Market share data not available.
Market Dynamics
Industry Overview
The biotechnology industry is rapidly evolving, with increasing focus on microbiome-based therapies. Phage therapy is an emerging field with potential to address antibiotic resistance and other unmet medical needs.
Positioning
BiomX is positioned as a leader in phage therapy development, with a focus on targeted microbiome modulation. The company's competitive advantage lies in its phage discovery platform and expertise in microbiome analysis.
Total Addressable Market (TAM)
The total addressable market for microbiome-based therapies is estimated to be in the billions of dollars. BiomX is positioned to capture a portion of this market through its targeted phage therapy products.
Upturn SWOT Analysis
Strengths
- Proprietary phage discovery platform
- Expertise in microbiome analysis
- Targeted therapies with potential for high efficacy
- Potential to address antibiotic resistance
Weaknesses
- Limited clinical data
- Reliance on successful clinical trials
- High development costs
- Uncertainty regarding regulatory approval for phage therapy
Opportunities
- Expanding pipeline of phage therapy products
- Partnerships with pharmaceutical companies
- Increasing awareness of the microbiome's role in disease
- Potential to address unmet medical needs
Threats
- Competition from other biotechnology companies
- Regulatory hurdles
- Clinical trial failures
- Funding constraints
Competitors and Market Share
Key Competitors
- ADPT
- CRSP
- EDIT
Competitive Landscape
BiomX is focusing on phage therapy for microbiome modulation. The company's competitors have a variety of therapeutic approaches.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to early stage. Growth tied to pipeline advancement.
Future Projections: Future growth dependent on clinical trial success and regulatory approval.
Recent Initiatives: Advancing clinical trials for BX001 and BX211.
Summary
BiomX is an early-stage biotech company focusing on novel phage therapies. Their strengths lie in their innovative platform, but significant risks exist with clinical trials and funding. Success hinges on advancing their pipeline and securing partnerships. Investors should carefully consider the high-risk, high-reward nature of the company. BiomX faces challenges in regulatory approvals and competition from established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomx Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2019-03-13 | CEO & Director Mr. Jonathan Eitan Solomon MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.biomx.com |
Full time employees 52 | Website https://www.biomx.com | ||
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.